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Purpose: The U.S. response to the SARS-CoV-2 epidemic has been hampered by early and ongoing delays
in testing for infection; without data on where infections were occurring and the magnitude of the
epidemic, early public health responses were not data-driven. Understanding the prevalence of SARSCoV-2 infections and immune response is critical to developing and implementing effective public
health responses. Most serological surveys have been limited to localities that opted to conduct them
and/or were based on convenience samples. Moreover, results of antibody testing might be subject to
high false positive rates in the setting of low prevalence of immune response and imperfect test
speciﬁcity.
Methods: We will conduct a national serosurvey for SARS-CoV-2 PCR positivity and immune experience.
A probability sample of U.S. addresses will be mailed invitations and kits for the self-collection of anterior
nares swab and ﬁnger prick dried blood spot specimens. Within each sampled household, one adult
18 years or older will be randomly selected and asked to complete a questionnaire and to collect and
return biological specimens to a central laboratory. Nasal swab specimens will be tested for SARS-CoV-2
RNA by RNA PCR; dried blood spot specimens will be tested for antibodies to SARS-CoV-2 (i.e., immune
experience) by enzyme-linked immunoassays. Positive screening tests for antibodies will be conﬁrmed
by a second antibody test with different antigenic basis to improve predictive value of positive (PPV)
antibody test results. All persons returning specimens in the baseline phase will be enrolled into a
follow-up cohort and mailed additional specimen collection kits 3 months after baseline. A subset of 10%
of selected households will be invited to participate in full household testing, with tests offered for all
household members aged 3 years. The main study outcomes will be period prevalence of infection with
SARS-CoV-2 and immune experience, and incidence of SARS-CoV-2 infection and antibody responses.
Results: Power calculations indicate that a national sample of 4000 households will facilitate estimation
of national SARS-CoV-2 infection and antibody prevalence with acceptably narrow 95% conﬁdence intervals across several possible scenarios of prevalence levels. Oversampling in up to seven populous
states will allow for prevalence estimation among subpopulations. Our 2-stage algorithm for antibody
testing produces acceptable PPV at prevalence levels 1.0%. Including oversamples in states, we expect to
receive data from as many as 9156 participants in 7495 U.S. households.
Conclusions: In addition to providing robust estimates of prevalence of SARS-CoV-2 infection and immune experience, we anticipate this study will establish a replicable methodology for home-based SARSCoV-2 testing surveys, address concerns about selection bias, and improve positive predictive value of

Keywords:
SARS-CoV-2 infection
Probability sampling methods
PCR testing
Serology
SARS-CoV-2 serology

* Corresponding author. Emory University School of Public Health, 1518 Clifton Rd, NE, Atlanta, GA 30030. Tel.: þ14047129733.
E-mail address: asiegle@emory.edu (A.J. Siegler).
1
Contributed equally.
https://doi.org/10.1016/j.annepidem.2020.07.015
1047-2797/© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

A.J. Siegler et al. / Annals of Epidemiology 49 (2020) 50e60

51

serology results. Prevalence estimates of SARS-CoV-2 infection and immune experience produced by this
study will greatly improve our understanding of the spectrum of COVID-19 disease, its current penetration in various demographic, geographic, and occupational groups, and inform the range of symptoms
associated with infection. These data will inform resource needs for control of the ongoing epidemic and
facilitate data-driven decisions for epidemic mitigation strategies.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction
The global pandemic of SARS-CoV-2 and its associated illness
(coronavirus disease 2019, or COVID-19) have emerged very
quickly, challenging traditional systems of clinical and public health
response [1,2]. There is broad consensus that the U.S. response to
the COVID-19 epidemic has been hampered by lack of adequate
testing for SARS-CoV-2 [3e6]. Globally, available statistics representing the scale and growth of the epidemic are based on the
numbers of people diagnosed and reported with SARS-CoV-2 infections and the number of people who have died from COVID-19
disease. These measures are informative but biased: diagnoses of
COVID-19 disease predominantly count people who were sufﬁciently sick and symptomatic that they were tested. Moreover, the
data are differentially biased by time and jurisdiction. Testing
policies have changed over time as test availability increases, and
testing policies in heavily impacted areas may be more restrictive
for people with mild illness than policies in less impacted areas.
Importantly, there are limited population-based data about the
proportion of people who become infected with SARS-CoV-2 who
remain asymptomatic or about the proportion of people who may
already possess antibodies to the virus.
Traditional public health surveillance programs that are linked
to disease prevention efforts focus on diagnosing people with an
infectious disease and then helping them take steps to minimize
the risks of onward transmission. Surveillance data to characterize
epidemics are often collected from testing and intervention programs, and surveillance data improve as public health screening
and testing programs grow. In the COVID-19 epidemic, the traditional public health model in the United States has been disrupted
because of how fast the epidemic emerged and limited testing and
contact tracing capacity. There are limited resources for testing in
terms of supplies (e.g., shortages of swabs for collection, viral
transport media, and personal protective equipment for health care
workers collecting invasive specimens) [7,8] and personnel to
collect samples. Because of these limitations, in many areas testing
resources have been focused on the sickest people, providing
testing data that present an underestimate of the true extent of the
epidemic and that differentially undercount mildly symptomatic
and asymptomatic people. Therefore, it is critical to develop a
representative depiction of the distribution of SARS-CoV-2 infection and immune experience to inform public health policies and
prevention and control interventions.
The ﬁeld of antibody testing is rapidly evolving, and our understanding of the clinical signiﬁcance of seropositivity is limited.
Local serosurveys using a variety of sampling methods have reported relatively low prevalence estimates for seropositivity
[9e11]. For low prevalence serosurveys, the predictive value of
positive antibody tests is a substantial issue. With overall prevalence ﬁndings in many surveys in the single digits, even slight
performance problems in speciﬁcity could result in substantial
changes in outcomes. For instance, if a serosurvey in a population
with “true” prevalence less than 6% uses an assay with less than or
equal to 97% speciﬁcity, most positive specimen ﬁndings would be
false positives. Moreover, serological surveys are a lagging indicator

of infection, with one study identifying median time to detectable
seroconversion to be 13 days postexposure across antibody types
[12] and another ﬁnding 15e20 days postexposure across antibody
types [13]. An additional concern of some existing methods, unrelated to bias, regards the appropriateness of conducting inperson testing in the face of limited availability of testing resources for persons who are ill and limited personal protective
equipment for health care workers. An optimal study design might
avert use of such resources.
To provide less biased estimates of prevalence of SARS-CoV-2
virus and immune experience, we propose a study design that
differs from previous studies in four critical ways. First, we propose
to use address-based sampling, commonly considered to be the
reference standard for developing population-representative estimates, with a sample frame that includes nearly all addresses in the
United States [14,15]. Second, we will use home specimen collection
and remote laboratory testing procedures, which have higher
acceptability than in-person specimen collection and can reach
otherwise hard-to-reach populations such as workers and persons
in rural areas [16]. Third, the use of a serology screening test followed by a high-speciﬁcity conﬁrmatory test will allow for
improved predictive value of positive specimens using antibody
tests that target different antigenic components. Finally, performing both viral detection and antibody testing will provide a
simultaneous understanding of the prevalence of viral shedding
(and potential infectiousness) and of the prevalence of antibodies
(and potentially immunity). In addition to an initial assessment of
prevalence, our initial survey will be a baseline for future serial
rounds of viral detection and serology testing, allowing for development of population-based, minimally biased estimates of incidence SARS-CoV-2 infection and immune experience, overall and in
key subgroups (e.g. racial/ethnic minorities, rural areas, speciﬁc age
groups).
Methods
We will use a national address-based household sample to
collect survey data on approximately 4000 U.S. participants by
collecting survey data and self-collected specimens for SARS-CoV-2
RCA PCR and serology testing. The overall design of the study is
illustrated in Figure 1.
National probability sampling frame
The study will use an address-based sampling (ABS) frame for
selection of a probability-based sample, a method commonly
considered the reference sampling strategy in the cell phone era,
due to its complete coverage of the U.S. households when
compared with telephone- and internet-based frames [14,15]. The
frame is based on the USPS Computerized Delivery Sequence File
that includes roughly 130 million residential addresses, covering all
residential delivery points in the United States [17]. Each address is
geocoded to a unique latitude and longitude before its related
geodemographic data from the Census and commercial databases
such as Experian are retrieved. Moreover, approximately 50% of
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Fig. 1. Schema for a national household probability sample to estimate prevalence and incidence of SARS-CoV-2 infection and immune experience.

addresses are matched to landline and/or cellular phone numbers
that will allow for implementation of a multimodal retention
approach and rigorous refusal conversion procedures. This frame,
constructed by Marketing Systems Group from the latest
Computerized Delivery Sequence File, has been previously used in
numerous health research studies [18e21]. For addresses in nonoversampling strata, each address will be selected with an equal
probability of selection method to ensure the most efﬁcient estimates at the national level. To increase geographic representation,
we will use systematic random sampling, in which the frame is
ordered by 9-digit ZIPþ4 ﬁrst. Next, a random starting point is
selected and every nth address after the random start is selected.
Drop units (multiunit addresses) in the frame each have a drop
count, and the frame will be expanded to account for drop units.
National sampling plan
The intial sample for this study will comprise 4000 households
selected across the nation using the ABS frame. We will use a twostage sampling methodology, whereby in the ﬁrst stage a representative sample of households will be selected, followed by a
random selection of one adult in each sample households. We will
assume a household-level response rate of 22% and anticipated 5%
rate for addresses that may be vacant or otherwise unreachable at
the time of survey administration for an overall yield rate of 20.9%
(22 %  95 %). Recent probability samples for COVID testing in
Atlanta [22] and Indiana [23] have achieved similar participation
rates. We believe this is a feasible yield rate because although
contingency valuations can overestimate willingness, a recent national online survey nonetheless found 88% of respondents reported willingness to participate in COVID specimen self-collection
research [24]. The total sample will therefore include at least 19,129
addresses (4000/0.209).

Invitations and kits will be sent in waves to allow adjustments
for observed response rates and underrepresentation of important
subgroups. If there is substantial nonresponse among racial/ethnic
minority groups in wave 1, we will oversample geographic areas
(e.g., Census blocks) with high representation of African American
and/or Hispanic/Latinx populations in subsequent waves. Oversampling strategies will be designed with a goal of attaining sample
sizes in racial/ethnic minority subgroups proportional to their size
in the underlying U.S. population, facilitating robust estimation for
each group. The ﬁnite population correction (N-n)/(N-1) will be
virtually equal to 1, rendering the difference between sampling
with or without replacement in subsequent waves a moot
distinction. All waves will be pooled for analysis, and during the
weighting process, design weights will be calculated to reﬂect any
oversampling that may be used during the address selection
[25,26].
State and locality oversamples
Study methods are amenable to developing locality-speciﬁc
estimates. We will target a total sample size of at least n ¼ 600
per state although oversampling, additional to the national 4000
household sample, to develop stable state-speciﬁc prevalence estimates for up to seven populous states (CA, FL, GA, IL, NY, TX, WA),
contingent on availability of resources. These states represent
different geographic regions of the United States and include some
states that were impacted early. For these oversampled states, we
will coordinate with state health departments to maximally inform
local public health efforts. Depending on resource availability, we
may also include additional oversampling for some states to
develop enhanced estimation ability to inform their local public
health needs. For instance, in GA, the total sample will include 1200
households with participation offered to all household members
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aged 3 years or older, allowing for greater precision of local estimation. In total, we anticipate an additional 5156 participants in
3495 households to participate in the state and full household
oversamples for a national total of up to 9156 participants in 7495
households.
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completing survey participants. Call center procedures such as
hours of operation, number of contact attempts, and handling of
participant questions will be adapted from procedures used in
other large surveys [29]. All study materials will be available in
English and Spanish. Study procedures have been approved by the
Emory University Institutional Review Board (protocol 00000695).

Household procedures
Enumeration and eligibility
All households selected will receive a ﬁrst-class letter introducing the study and its website, an evidence-based practice
demonstrated to increase survey response [27]. The study website,
hosted on an academic server and featuring multimedia content,
will provide basic information regarding the study, address common participant questions, and encourage participant conﬁdence
in the study. Each household for which a consent and baseline
survey is completed will receive a home participation kit (HPK) in a
study-branded box (with branding consistent with the welcome
letter) that will detail how they can participate in the research if
they are interested. We may assess whether distribution of HPK to
households concurrent with the invitation letter increases participation. The HPK will include (1) instructions on accessing electronic or phone procedures for consent, enumeration, and
behavioral survey and (2) instructions and materials for selfcollection of specimens and return mailing to our central laboratory for testing. Specimen self-collection materials will include a
ﬂocked swab for collection of anterior nares specimens and a
transport tube containing phosphate-buffered saline; for selfcollection of dried blood spot (DBS) cards, the kit will include a
ﬁnger stick device, alcohol wipe, adhesive bandage, and Whatman
5-spot DBS specimen card.
The HPK will have a unique identiﬁer code that will be used for
all baseline procedures, including laboratory testing, incentives,
and survey. Instructions will direct participants to an online link or
toll-free call for screening consent and the household enumeration
procedure (detailed in the following). After the household
enumeration is complete, one adult household member will be
randomly selected based on an automated algorithm in our survey
platform. The selected person will be asked to complete the study
consent and baseline questionnaire. Households not completing
the enumeration survey will receive two additional postcard reminders to complete the questionnaire and home test kit. Using a
multimodal approach, households in the sampling frame with
phone numbers (approximately 50%) and those who provided their
contact information at enrollment will also receive up to three text
messages and/or calls as additional reminders from a call center
specializing in research partnerships. Households will have a onemonth period to complete their kits for inclusion in the study.
We will adjust for differential nonresponse for households lacking
phone number information by using information available at the
Census block level [28]. Consenting persons who complete baseline
participation will be enrolled into an incidence cohort for a followup period. We will use similar contact procedures, and HPK, to
encourage follow-up participation at 3 months after the baseline
survey.
Consent and survey processes
All consents and survey data will be hosted on a secure, HIPAAcompliant electronic survey platform. Participants will be able to
self-complete the consent and surveys directly in the online platform or can call a toll-free number to have assistance in completing
these processes. Participants who wish to complete surveys by
phone will be assisted by staff trained in human subjects protocols
and study-speciﬁc procedures, with trained staff entering data into
the same secure electronic platform as the one used by self-

The enumeration process will be adapted from procedures used
in other national studies [29]. An adult aged 18 years or older in the
household will complete enumeration, providing for each member
of their household ﬁrst, middle, and last initials, age, gender. One
adult aged 18 years or older be randomly selected from the
enumeration list to complete the baseline questionnaire and HPK.
There is no exclusion criterion other than age. Persons who have a
clotting disorder, are on blood thinners, or are aged 80 years or
older will only complete the anterior nares specimen procedure.
Specimen self-collection
The sampled household member will be asked to use the HPK to
provide two specimens for laboratory testing. An anterior nares
(nasal) swab will allow for detection of SARS-CoV-2 RNA by RNA
PCR; The CDC identiﬁes at-home self-collected anterior nares
swabs as a suitable specimen type for PCR analysis [30], and selfcollected anterior nares swabs have high sensitivity for RNA
detection when compared with NP swabs [31]. Swabs will be stored
and shipped in phosphate-buffered saline. Participants will also
perform a ﬁnger prick with an automated lancet and ﬁll in a
Whatman 903 protein saver specimen card for the detection of
antibodies to SARS-CoV-2 [8]. Specimen collection instructions will
represent standard instructions, similar to those we have previously published for self-collected specimens [32,33], customized
with branding for this study. Instructions will also include videos
that demonstrate each component of the self-collection process
[34]. Instructions guide participants to return specimens within
48 hours of collection. Stability testing indicates a longer window,
allowing for shipping and laboratory processing time. Laboratorians will determine adequacy of sample based on visual inspection of the specimen and of the date collected and will request
retesting for specimens not determined to be adequate. All specimens will be returned through U.S. mail to the central study laboratory in biohazard bags and sturdy outer boxes.
Survey instrument
The 15e20 minute baseline questionnaire will assess domains of
demographics, COVID-19 knowledge, SARS-CoV-2 testing history,
medical history, symptomatic history, illness in household, social
distancing and isolation practices, and life changes due to COVID-19
(Supplement 1). Demographic measures will be adapted from the
Census Bureaus’ American Community Survey [35], and include
age, race/ethnicity, gender, education, income, and health insurance. COVID-19 knowledge items will be adapted from several
sources, focusing on information relevant to protective and proactive health behaviors. SARS-CoV-2 testing history will be based
on items previously used for HIV testing history in validated
questionnaires [36]. We will assess symptom history at two time
points relevant for virus and antibody testing, respectively, using 1month recall and time since January 2020. Clinical history will be
based on symptomology of COVID-19 identiﬁed by the U.S. Centers
for Disease Control and Prevention, and will use a severity index for
experienced symptoms based on an instrument validated for ﬂu
[37]. A number of studies have used different considerations to
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classify persons as “mildly” or “moderately” symptomatic for
COVID-19 disease, including assessments based on fever [38e40],
respiratory symptoms and their severity [38,40e42], cough [39],
nonspeciﬁc or other symptoms [38,39], and risk factors [42], yet
there is not currently a consensus method to assess symptoms
remotely [43]. We are therefore implementing a broad list of
symptoms and severity assessments to allow for us to meet
emerging consensus deﬁnitions for case classiﬁcation. Social
distancing and isolation practices will be based on measures previously used to inform modeling studies, assessing the number of
persons with close contact [44,45].

undergo a standard antibody extraction method using TRIS buffer.
Once the material is added to the reaction tube, the enzyme
immunoassay primary and secondary antibodies (SARS-CoV-2
assay, total immunoglobulins; BioRad) will be added using an
automated liquid handler instrument (DSX; Dynex Technologies,
Chantilly, VA). All serologic and molecular tests have FDA Emergency Use Authorization (EUA). The protocol will follow the manufacturer's guidelines for reaction conditions, data interpretation,
and control checks. For specimens with reactive results on the
screening test, a second eluate will be tested with the conﬁrmatory
test using the same elution procedures.

Laboratory testing

Return of results
If use of study assays with self-collected specimens has been
approved or cleared under EUA by the FDA at the time of testing,
laboratory results will be returned to participants and they will be
instructed to seek follow-up care with their usual physician if they
have concerns or questions about their results. Results of the
overall antibody algorithm will be reported (e.g., if negative on ﬁrst
test, a nonreactive result will be reported; if positive on both tests, a
reactive result will be reported). For specimens with discordant
results, a third antibody test on a different platform will be run as a
tiebreaker and the result of the tiebreaker test will be reported. If
the assays used in the study have not received EUA, we will return
test results as research results to the extent allowable by the FDA,
under the auspices of Emory's IRB approval and an informed consent process. For specimens with insufﬁcient quantity or other
extraction failure, participants will be mailed an additional kit to
allow for repeat specimen collection.

RNA PCR
Anterior nares swab specimens will be processed as previously
described [34]. Specimens will ﬁrst be checked for quality. The
samples will then undergo total nucleic acid extraction using the
Thermo Kingﬁsher platform (Fisher Scientiﬁc, Waltham, MA). Isolated RNA will be reverse-transcribed to DNA using a one-step, onetube system using reagents from Thermo (Fisher Scientiﬁc). The
second half of the one-tube system will involve qPCR. The reversetranscribed DNA will undergo qPCR with primers and probes targeting three gene regions of the SARS-CoV-2 genome (N, S, ORF1),
using reagents from Thermo. The results will be analyzed and an
interpretation will be made based on cycle threshold values and
positive identiﬁcation of the nucleic acid.
Serology tests
A two-step process will be used: all specimens will be tested
with a screening ELISA, and all specimens testing positive on the
screening assay will also be tested a second time with a second
ELISA. We implement this strategy by screening with a test with
relatively high sensitivity to detect total antibodies (BioRad, Hercules, CA: Sens: 92.2%; Spec: 99.6% for IgG, IgM, and IgA) and
conﬁrming with a test with high speciﬁcity for IgG and IgA
(EUROIMMUN IgG, Mountain Lakes, NJ; Sens: 90%, Spec: 100%;
EUROIMMUN IgA performance not yet documented by FDA) [46].
This combination of conﬁrmatory isotypes addresses both early and
long-term immune responses, and IgA appears at approximately
the same time after infection as IgM and at higher concentrations
[47]. Based on the FDA-evaluated sensitivity and speciﬁcity of the
two tests, the predictive value of the algorithm for a positive test
(PPV) is 100% in all cases, and the predictive value of a negative test
(NPV) ranges from 99.4% to 99.99%, depending on prevalence of
antibodies in the population (Table 1). Performance data from FDA
also contain 95% conﬁdence intervals (CIs) for sensitivity and
speciﬁcity of tests. If worst-case scenarios (e.g., the lower 95% CI for
sensitivity of the screening test and the lower 95% CI for the
speciﬁcity of the conﬁrmatory test), predictive value of positive
tests has more variability, especially for low prevalence scenarios.
DBS specimens will ﬁrst be checked for visual quality [34]. A
6 mm punch will be obtained from the DBS and the material will

Primary outcomes
The primary outcomes will be (1) the weighted proportion and
95% CI of SARS-CoV-2 RNA-PCR detected specimens and (2) the
weighted proportion and 95% CI of SARS-CoV-2 persons with
detectable antibodies (i.e., algorithm-determined positive). These
outcomes will be prepared with inference to the United States and
to the oversampled states. Table 2 provides more detail regarding
study outcomes.
Data system
A uniﬁed data system that leverages information from research
partners will be used for participant management. Figure 2 represents the data sources, including sources of participant-related data
(call center, survey data, laboratory data, and incentive), which will
be combined with data from Emory and from the sample frame
provider into a secure, uniﬁed cloud-based participant data management system (DMS). The DMS will allow for real-time tracking
of participant progress in the study, and system-automated responses to facilitate scalability and rapid response. This is best
illustrated with a description of how participant data will ﬂow
through the system. The sample frame provider will enter the list of

Table 1
Performance of an alogorithm to detect immune response to SARS-CoV-2 infection, by population prevalence and for overall, best-case and worst-case estimates of sensitivity
and speciﬁcity
Population Prevalence

0.1%
1%
2%
5%
*

FDA estimated

Worst case*

Algorithm PPV

Algorithm NPV

Algorithm PPV

Algorithm NPV

100%
100%
100%
100%

99.99%
99.89%
99.78%
99.4%

29.6%
80.9%
89.6%
95.7%

99.9%
99.89%
99.77%
99.41%

Worst case utilizes the lower 95% CI for sensitivity for the screening test, and the lower 95% CI estimate of speciﬁcity for the conﬁrmatory test.
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Table 2
Outcomes for a national serosurvey for COVID-19 infection and immune experience
Study data source

External data source

Answerable question

Outcome measure

Analysis

Baseline PCR tests

U.S. Census for
weighting

Prevalence of COVID-19 disease

Period prevalence

Baseline antibody (Ab) tests

U.S. Census for
weighting
U.S. Census for
weighting
U.S. Census for
weighting
U.S. Census for
weighting
Public diagnosis data

Prevalence of SARS-CoV-2-speciﬁc immune
response
Incidence of COVID-19 disease

Period prevalence
Period incidence

Incidence of SARS-CoV-2-speciﬁc immune response

Period incidence

Prevalent exposure to SARS-Cov-2 (PCR or AB test)

Period prevalence

Estimated proportion of SARS-CoV-2 cases that lead
to diagnosed COVID-19

Proportion

Upweighted estimates,
conﬁdence intervals
(CIs)
Upweighted estimates,
CI
Upweighted estimates,
CI
Upweighted estimates,
CI
Upweighted estimates,
CI
Upweighted estimates,
CI sensitivity analyses
on diagnosis data
Upweighted estimates,
CI sensitivity analyses
on fatality data
Upweighted estimates,
CI
Upweighted estimates,
CI
Weighted regression
estimates

Baseline þ follow-up PCR, Ab
tests
Baseline þ follow-up PCR, Ab
tests
Baseline þ follow-up PCR, Ab
tests
Baseline PCR, Ab tests, reported
diagnosis
Baseline PCR, Ab tests

Public NDI data, excess
mortality data

Estimated proportion of SARS-CoV-2 cases that lead
to fatality

Proportion

Baseline PCR, Ab tests, reported
symptoms
Baseline PCR, Ab tests, reported
perception
Baseline PCR, Ab tests, selfreport survey measures

U.S. Census for
weighting
U.S. Census for
weighting
U.S. Census for
weighting

Estimated proportion of SARS-CoV-2 cases
asymptomatic or mildly symptomatic
Estimated proportion of SARS-CoV-2 cases that
perceived themselves as infected
Predictors of positive COVID-19 disease such as
social distance, occupation, family structure

Proportion

randomly selected addresses in the sample frame into the DMS,
allowing mailing of invitation letters and for the laboratory to mail
an HPK to the selected address. The sending of an HPK will be
registered in the DMS, for management purposes. When the
household respondent completes their questionnaire, the DMS will
receive notiﬁcation of this from the survey automated programming interface (API). After a participant has completed their specimen self-collection and returned the specimen to the laboratory,
the laboratory API will place completion data into the DMS, which

Proportion
Odds ratios

will trigger the DMS to automatically order a $40 electronic
incentive card to be provided to the participant, using the API of the
gift card provider. In addition, the DMS will communicate to the call
center that further follow-up calls should cease. The system will be
built to accommodate different participant pathways, such as for
participants who need additional reminders or have opted out of
study participation. Study staff will remotely manage the DMS and
participant contact process, ensuring participants needs are met
and that those interested in participating are on target to complete

Fig. 2. Uniﬁed study data system ﬂowchart.
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study tasks in a timely manner. The overarching goal of developing
the data system, and engaging with external partners accustomed
to handling large volumes of interactions including the study call
center, sampling partner, and laboratory, is to facilitate feasibility of
conducting the project on an expedited timeline.

positives; we will nonetheless account for imperfect performance
of the overall test algorithm sensitivity and speciﬁcity. We will use
the procedures proposed by Diggle, implemented in a Bayesian
framework, such that uncertainty from design effects and diagnostic inaccuracy are both quantiﬁed in prevalence estimates [48].

Primary analysis

Study sample size estimation

Sample weights will be computed and applied to generate estimates of study outcomes that are representative of the United
States and of the oversampled states of interest. First, base (inverse
probability) weights will be computed to reﬂect selection probabilities for both households and persons within households. Next,
poststratiﬁcation weights will be computed by ratio-adjusting base
weights to characteristics of the survey population, based on the
latest population estimates from the Census American Community
Survey. For this purpose, we will use a “raking” procedure to ensure
alignment with the U.S. population (and oversampled states) with
respect to various geodemographic characteristics, including
gender, age, race-ethnicity, education level, region, income, home
ownership, and metropolitan area. The resulting design effect,
P ðwi wÞ_ 2
which can be approximated by d ¼ 1 þ i _ 2n1 , will be examined to

Early serosurvey data have identiﬁed a range of antibody
prevalence values, 2.8% weighted prevalence in Santa Clara County
[10], 4.3% antibody prevalence in Los Angeles County [11], and
12.3% in New York state [9]. Figure 3 displays the overall margin of
error as a function of different sample sizes and prevalence levels.
In Table 3, we present margins of error for assessing antibody
prevalence for our national sample, given our proposed 4000person national sample. We ﬁnd that a scenario with 2% prevalence of infection or immune experience would have a margin of
error (MoE) of ±0.43, with 5% prevalence a MoE ±0.68%, and 10%
prevalence a MoE ±0.93%. We also anticipate acceptable margins
for subgroup analyses, for instance persons 18e39 years old 2%
prevalence scenario with MoE ±0.80%, 5% prevalence a MoE ±1.24%,
and 10% prevalence a MoE ±1.71%. In Table 4, we present similar
estimates for a statewide sample of 600 persons in New York State.
For other oversampled states, these numbers are substantially
similar, although differing marginally due to differences in the
distributions of age and gender. When sample weights are applied
to estimates, MoE may increase. All estimates are based on a twosided interval, with alpha ¼ 0.05.

w

assess the weighting efﬁciency. We will use Taylor series linearization for variance estimation.
We will develop weighted estimates for study outcomes,
including period prevalence and incidence of SARS-CoV-2 infection
and SARS-CoV-2-speciﬁc immune response, estimates of the proportion of cases that lead to diagnosed COVID-19 or to fatality, and
of the numbers and proportions of cases that are mildly symptomatic or asymptomatic. We will create estimates for each of these
main outcomes for subgroups including age group, gender, race/
ethnicity, symptomology, region, and urbanicity.
We will conduct a series of analyses using regression models
appropriate for each type of data, such as logistic regression models
for assessment of the predictive utility of various symptoms on
prevalence of study outcomes. Several sensitivity analyses will be
conducted to assess potential bias, such as full household estimation (more detail in the following) to explore potential deviations
from random selection of household members, and a separate
analysis to assess the impact of enumerated household members
who are unavailable to participate because of hospitalization for a
respiratory condition. It will also be important to correct for known
imperfection in the diagnostic performance of laboratory tests. Our
conﬁrmatory testing procedure will serve to minimize false

Full household assessment
Our study design calls for testing a single household member,
based on a rationale that full household testing would likely reduce
response rates (leading to bias) and that the additional laboratory
testing would greatly add to the study cost without substantially
increasing study power due to within-household correlation of
outcomes. There is potential for bias in selecting a single household
respondent: some households will be more likely to select a
member who has symptoms, leading to overestimation of primary
outcomes. Conversely, other households may have one member
who is sick and assumed to have COVID-19, and they may instead
test a household member with more mild symptoms, leading to
endpoint underestimation. To describe potential bias in selection of
a single household member for testing, we will randomly select a
group of households to receive additional testing for all household
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Table 3
Margin of error as a function of period prevalence estimate and demographic categories for estimation for a national sample of 4000 persons
Prevalence

2%
5%
10%
20%
30%
40%
50%

National estimate

18e39 y

40e59 y

60þ y

Males

Females

n ¼ 4000

n ¼ 1181

n ¼ 1004

n ¼ 905

n ¼ 1961

n ¼ 2039

±0.43%
±0.68%
±0.93%
±1.24%
±1.42%
±1.52%
±1.55%

±0.80%
±1.24%
±1.71%
±2.28%
±2.61%
±2.79%
±2.85%

±0.87%
±1.35%
±1.86%
±2.47%
±2.83%
±3.03%
±3.09%

±0.91%
±1.42%
±1.95%
±2.61%
±2.99%
±3.19%
±3.26%

±0.62%
±0.96%
±1.33%
±1.77%
±2.03%
±2.17%
±2.21%

±0.61%
±0.95%
±1.30%
±1.74%
±1.99%
±2.13%
±2.17%

members aged 3 years or older. We will target participation of 400
households, or 10% of households in the national sample, for this
purpose. Based on the proportion of single-person households, and
average U.S. household size of 2.6 [35], we anticipate this will lead
to an additional 396 tests and surveys, allowing for assessment of
possible bias in selection of household members for testing. Potential bias will be characterized by comparing test positivity by
participant characteristics among fully sampled households to
standard households in which one person was sampled. This subset
of fully enumerated households will additionally allow for characterizing within-household transmission for households with
symptomatic and asymptomatic positive members.
Incidence cohort design
Participants completing baseline procedures will be mailed
identical follow-up testing kits at 3 months after the return of their
initial test, regardless of the baseline SARS-CoV-2 infection and
immune experience at the baseline. We will retest participants using the same laboratory methods as for baseline testing and calculate incidence in the period for each laboratory assessment by
calculating the weighted number of participants with newly positive assessment at time T1/the weighted number of susceptible
people at time T0. Persons testing PCR- or serology-positive will be
retested at the follow-up period to characterize ongoing viral
shedding, development of SARS-CoV-2-speciﬁc antibodies and
behavioral changes at subsequent time points. This will allow for
improved understanding of these outcomes for a representative
sample of persons who are asymptomatic or mildly symptomatic. In
past studies we have observed 80% cohort retention [32,49e51]; we
anticipate slightly lower (70%) retention at 3 months for this cohort
study. We may also include additional incidence- or resampleassessment time points based on the interests and identiﬁed
needs of collaborating state and local health departments.
Transmission model analyses
Seroprevalence data serve as a key input into dynamic transmission models of infectious disease [52,53]. For SARS-CoV-2,

susceptible, exposed, infectious, and recovered model frameworks are being widely used for a range of applications including
forecasting, inferring transmission patterns, and examining the
potential impact of interventions such as social distancing [54e57].
We will use our study's estimates of seroprevalence to set the size
of the R (recovered) compartment in both simple and agestructured transmission models, thereby increasing the realism of
the model scenarios. Our seroprevalence estimates can also be used
by the wider modeling community to reﬁne other models for a
range of applications. We will speciﬁcally use our seroprevalence
estimates to model how social distancing can be relaxed in an
acceptable safe manner. In doing so, we will investigate how
serological testing at the individual and population level may
provide data for public health actions.
Results
Participant recruitment and data collection began in July 2020.
We will report the main outcomes, of period prevalence of infection
with SARS-CoV-2 and SARS-CoV-2-speciﬁc immune response, by
variables including symptoms, symptom history, underlying conditions, county population concentration (urbanicity), region,
gender, age, family size, and isolation practices. Given the urgent
nature of the pandemic, we will develop a study website for results
dissemination to supplement reporting of study outcomes through
academic publication. The study website, COVIDVu.org, will serve
as a venue to report preliminary prevalence estimation, as a portal
for sharing nonidentifying public use study data sets, and to share
infographics to communicate key study ﬁndings to a broader
audience.
Discussion
The COVID-19 pandemic has had wide-reaching economic and
social impact in the United States: most daycares have closed,
students are receiving virtual schooling, adults with nonessential
positions are teleworking, and many persons have lost their jobs,
are working fewer hours, or are being furloughed. For policy
makers to be best informed, it is critical to have high-quality,

Table 4
Margin of error as a function of period prevalence estimate and demographic categories for estimation for a state sample of 600 persons
Prevalence

2%
5%
10%
20%
30%
40%
50%

New York state sample

18e39 y

40e59 y

60þ y

Males

Females

n ¼ 600

185

152

138

292

308

±1.12%
±1.74%
±2.40%
±3.20%
±3.67%
±3.92%
±4.00%

±2.02%
±3.14%
±4.33%
±5.77%
±6.61%
±7.07%
±7.21%

±2.23%
±3.47%
±4.77%
±6.36%
±7.29%
±7.79%
±7.95%

±2.34%
±3.64%
±5.01%
±6.68%
±7.65%
±8.18%
±8.34%

±1.61%
±2.50%
±3.44%
±4.59%
±5.26%
±5.62%
±5.74%

±1.56%
±2.43%
±3.35%
±4.47%
±5.12%
±5.47%
±5.58%
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minimally biased data regarding the current status of the epidemic.
Several local surveys to establish antibody prevalence have been
launched to better characterize local epidemics. In New York State,
a sample of over 15,000 persons recruited at grocery stores and
community centers during April and early May found overall
antibody prevalence of 12.3%, with wide ranges of prevalence from
1.2% in North Country to 19.9% in New York City [9]. In Los Angeles
County, a survey of 1952 adults selected from a proprietary database representative of the county (maintained by a market research
ﬁrm) had 865 participants (50.9%) and found 4.3% weighted antibody prevalence (95% CI: 2.6%e6.2%) [11]. In Santa Clara County, CA,
a widely criticized study with convenience sample of 3300 residents had 1.5% (95% CI: 1.1%e2.0%) unweighted antibody prevalence, with weighted estimate of 2.8% (95% CI: 1.3%e4.7%) [10]. The
CDC conducted serosurveys with door-to-door outreach using
probability samples in two Georgia counties and the State of Indiana in AprileMay 2020; the results suggested 2.6% (95% CI: 1.1%e
6.3%) and 2.8% (95% CI: 2.0%e3.7%), respectively [22,23].
Such assessments are important, but the nonprobability studies
are subject to several key areas of potential bias. Because of convenience sampling, data from some of these surveys may not be
representative of the underlying population. Persons seeking
testing, or willing to receive testing, may be more likely to have
experienced illness. Conversely, for household-based testing with
health careeworker specimen collection, persons who are working
and at higher risk of exposure may not be home for such assessments. Nonrepresentative surveys may also not be able to
adequately speak to less advantaged communities, whether in rural
areas or in lower-income urban settings.
We propose to leverage a probability sample and home-based
testing to produce estimates of the prevalence of SARS-CoV-2
infection and SARS-CoV-2-speciﬁc immune response that will
include people without symptoms, who might otherwise not seek
testing, and who might be unable to travel to a testing location or
who might be unwilling to test at a clinical site for testing. This
latter concern is important: our preliminary data indicate that
nearly half of people may be unwilling to attend a laboratory
testing venue for SARS-CoV-2 as part of a research study [24].
Higher participation rates will minimize selection bias. Importantly, willingness to participate in a home test study for COVID-19
was high overall, and not differential across key demographic variables such as age and race/ethnicity [24]. Furthermore, our mailbased testing platform is highly acceptable to participants [32],
and initial evaluation of self-specimen collection indicated that the
great majority of participants are able to self-collect specimens for
SARS-CoV-2 PCR and serology testing [33]. To date, a number of
important studies on the prevalence of antibodies have been biased
because they likely reﬂected an over-representation of people
seeking care [9,10,58]; because they recruited people in ways that
encouraged those concerned about their possible exposures to
participate [10]; and because they recruited at convenience locations where attendance in a venue might be selectively associated
with lower perceived vulnerability to infection [9]. A probabilitybased, nationally representative survey will provide a context
through which to understand studies that are local and/or based on
convenience samples.
We recognize that our strategy, while emphasizing representativeness and minimizing selection bias, has important limitations. Some critical populations will not be reached with our
sampling strategy. For example, people who are homeless or who
reside in informal lodgings without individual postal addresses will
be missed in our sampling; this is an important limitation because
there is evidence that homeless persons may be at especially high
risk [59]. People who are incarcerated will also be excluded and are
also at high risk [59]. It is critical that other types of

serosurveillance efforts be developed and implemented to
compliment household probability-based serosurveys; triangulation based on an understanding of the weaknesses of a surveillance
system is a well-accepted approach to develop an overall understanding of the impact of a health condition [60,61].
Our approach is vulnerable to nonresponse at the baseline, and
challenges with retention at the follow-up period. We will attempt
to mitigate nonresponse by maximizing opportunities for participants to corroborate the authenticity of the study: using distinctive,
professional branding that will be recognizable across interactions;
providing a website that will be hosted on an academic web platform with multiple modes of information about the study (e.g.,
video, FAQ formats); and by mailing a professionally branded and
designed home participation kit to all selected households. We will
assess for differential nonresponse by characteristics of the census
tract of selected participantsdfor example, median income, racial/
ethnic distribution, health insurance coverage, health literacy, etc.,
and weight to adjust for such nonresponse. We have estimated that
we will have 22% response, a level lower than reported willingness
to participate in home testing studies for COVID-19 research [24], to
account for the possibility that the willingness contingency valuation overestimated willingness. We will seek to enhance retention
abilities by collecting a full set of detailed contact information at the
baseline, and by using multiple modes of contact strategies at
follow-up, strategies we have successfully used in other remote
home testing studies [32,62,63]. We will perform analyses at the
follow-up period to assess ways in which differential retention
across subgroups might impact study ﬁndings. We will also seek to
consider the impact of nonresponse and loss to follow-up by
considering data triangulation, assessing data across different
sources including other infection and antibody surveys and local
case surveillance data.
Data for public health action are most powerful when they are
most local. Our proposal aims to develop national estimates with
systematic sampling to ensure adequate geographic diversity. It
also represents a framework and a set of tools that will be applied
to state-level estimation and could be expanded to smaller jurisdictional levels such as metropolitan areas. As part of the initial
study, we will also collect data to develop overall state-level estimates of RNA PCR and antibody positivity for a number of highly
populated states.
Understanding the prevalence of SARS-CoV-2 infection and
SARS-CoV-2-speciﬁc antibodies that might indicate immunity can
provide the roadmap to estimating levels of required resources, to
improving our understanding of the spectrum of COVID-19 disease,
and to understanding the differences in infection in key subpopulations in the U.S. epidemic. By combining traditional methods
of recruiting a representative sample with novel methods to allow
laboratory assessment of participants without requiring participants to visits a clinical location for specimen collection, we will be
able to represent all housed persons in the United States, including
otherwise hard to access populations such as people who live in
rural areas and people who are hesitant to go into health care
settings because of concern of contracting the virus. Public health
surveillance is the conscience of an epidemic [64]; our planned
national survey will be an important data source that will provide a
representative national picture and help to put case reporting and
other types of serosurveys in context.
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